ERBB2 and glioblastoma: In GBM, this method has been used in a subset of patients with IL-13Rα and human epidermal growth factor receptor 2 (HER2) mutations; however it has been most extensively studied in the subpopulation of patients with EGFRvIII mutations [140,141,142,143,144].